Genmab Stock Tests $33 as Royalty Model Fuels Earnings Transition
0h ago|5 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
genmabbiotechnology
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. AiX is informational software — not investment advice. Past performance does not guarantee future results.
Genmab A/S (GMAB) shares traded lower, closing at $33.23, down 1.54% on the session, as investors assessed the company's ongoing pivot toward a royalty-driven revenue model. The stock moved within a daily range of $33.12 to $33.93, reflecting tempered activity as markets evaluate the long-term implications of this strategic shift. This movement follows recent analysis highlighting royalty growth as a potential catalyst for a new earnings cycle for the Danish biotech firm. As of 22:19 UTC today, the market is weighing the stability of royalty streams against the historically higher margins of proprietary drug sales.
The strategic shift for Genmab arrives at a critical juncture for the biotechnology sector, which faces heightened pressure from patent cliffs and increased regulatory scrutiny. The last significant transition to a royalty-focused model for a major biotech occurred when BioMarin Pharmaceutical re-evaluated its rare disease portfolio in late 2023, leading to a sustained re-rating of its shares by approximately 18% over the subsequent six months. The current macro backdrop for healthcare equities is defined by the US 10-year Treasury yield hovering near 4.3%, which pressures growth-oriented valuations but can enhance the appeal of predictable income streams. The immediate catalyst for Genmab appears to be the maturation of its partnered assets, particularly the antibody-drug conjugate Tivdak and the bispecific antibody Epkinly, which are now generating escalating royalties from partners like Seagen and AbbVie. This transition reduces the company's direct commercial execution risk and operational costs, fundamentally altering its earnings profile from a high-risk developer to a more stable income-generator. The move is a direct response to investor demand for visibility following volatile quarterly results tied to its own commercial efforts.
Genmab's stock performance reflects a period of consolidation as the market digests its new financial profile. The share price of $33.23 gives the company a market capitalization of approximately $21.5 billion. The stock's 1.54% decline today contrasts with a year-to-date performance that has lagged the iShares Biotechnology ETF (IBB), which is up 5.2% for the year. Genmab's 52-week trading range is vast, from a low of $28.10 to a high of $42.75, indicating significant volatility as its strategy evolved. The company's most recent quarterly earnings report showed royalty and milestone revenue growing to $165 million, a 22% increase year-over-year, while total revenue from product sales declined by 8%. This divergence highlights the core of the transition. The following table illustrates the changing revenue composition over the past two reporting periods.
| Revenue Source | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Royalty & Milestone | $165M | $135M | +22.2% |
| Product Sales | $310M | $337M | -8.0% |
Analyst price targets for GMAB show a wide dispersion, with a consensus near $38.50, suggesting a potential 16% upside from the current price, though the lowest targets sit at $30, just below current levels.
The shift to a royalty-centric model has clear second-order effects across the biotech ecosystem. Companies with similar partnered portfolios, such as argenx SE (ARGX) and Immunocore Holdings (IMCR), may see increased investor interest as the market warms to the derisked growth narrative. Conversely, pure-play commercial-stage biotech firms facing sales execution challenges, like Sarepta Therapeutics (SRPT), could face heightened scrutiny regarding their capital allocation. The royalty model directly benefits Genmab's bottom-line stability, potentially expanding its earnings multiple if the income is perceived as durable. A key risk to this thesis is concentration; a significant portion of near-term royalty growth is tied to a small number of assets, making the company vulnerable to clinical or commercial setbacks with those specific drugs. Flow data indicates institutional investors have been net buyers over the past month, with a notable increase in call option volumes, suggesting a build-up of long positioning betting on a successful re-rating. This activity contrasts with retail investor sentiment, which has been more cautious, reflected in higher-than-average selling pressure on minor downticks.
The immediate catalyst for Genmab will be its Q3 2026 earnings release, projected for early November 2026, where investors will scrutinize the royalty growth rate versus the decline in direct sales. The American Society of Hematology (ASH) annual meeting in December 2026 will provide critical clinical updates for Epkinly, which could significantly influence future royalty projections from partner AbbVie. Key technical levels to monitor include a support zone around $32.50, which has held twice in the last quarter, and resistance near the 200-day moving average, currently sitting at $34.80. A sustained break above this average on strong volume would signal bullish conviction in the new earnings narrative. The direction of the broader market, particularly the XBI biotech ETF, will also be a factor; if sector sentiment improves, GMAB's unique royalty story could attract disproportionate inflows. Approval decisions for supplemental indications for its partnered drugs in international markets throughout late 2026 and early 2027 represent additional near-term milestones.
A royalty-based revenue model typically reduces earnings volatility because income is tied to a partner's sales volume rather than a company's own marketing and distribution costs. For Genmab, this means quarterly results may become more predictable, potentially lowering the stock's beta. However, volatility could spike around events affecting its partners, such as clinical trial results or regulatory decisions for the specific drugs generating royalties. The stock's historical range suggests it is still susceptible to sector-wide biotech sentiment shifts.
Genmab's royalty model is distinct from a dedicated royalty monetization firm like Royalty Pharma (RPRX). Genmab generates royalties from assets it originally discovered and developed, meaning it retains significant scientific involvement and future option rights. Royalty Pharma acquires finished royalty streams passively. Genmab's model offers potential for higher growth from its pipeline but carries more biotech-specific risk, whereas RPRX offers greater diversification across many drugs and therapeutic areas, resulting in a lower-risk, income-focused profile.
Historical precedents are mixed. BioMarin's shift in 2023 was rewarded with a higher valuation, as its royalties were from established products. In contrast, companies like Vertex Pharmaceuticals in the early 2010s initially saw multiple compression when moving away from direct sales, as investors feared capped upside. The outcome for Genmab hinges on whether the market views its royalty streams as a bridge to future proprietary products or as the long-term core of the business, with the latter typically commanding a lower growth multiple.
Genmab's transition to a royalty-heavy earnings cycle offers stability but tests investor appetite for growth beyond its core antibody platform.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
AiX is our free MetaTrader 4 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. XAUUSD breakout engine.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.